Skip to content
MatchScript
Menu

Head-to-head · The Match Score

CoreAge Rx vs TeleCareSpot

Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 65 edge.

Higher Match Score

CoreAge Rx

#1 · Grade A−

Anyone who wants transparent flat pricing, fast nationwide access, and no teaser-rate bait-and-switch.

Visit CoreAge Rx
VS

TeleCareSpot

#206 · Grade C

People who want flat-priced, LegitScript-verified compounded semaglutide or tirzepatide with broad state coverage.

Visit TeleCareSpot

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
44
Speed to Start
97
86
Formulary Match
80
77
Support Level
93
76
Flexibility
97
61
Transparency
95
50

Price, coverage & formulary

DetailCoreAge RxTeleCareSpot
Semaglutide$149/mo$299/mo (all doses, plus a separate fee, compounded)
Tirzepatide$349/mo$399/mo
CoverageAll 50 states48 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyYes
Match Score91 · A−65 · C
Winner: CoreAge Rx

CoreAge Rx is our #1-ranked provider overall, and it takes this matchup too — a 91 Match Score to TeleCareSpot's 65. The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.

TeleCareSpot is still a fair pick if its strengths line up with yours — best for: People who want flat-priced, LegitScript-verified compounded semaglutide or tirzepatide with broad state coverage.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full CoreAge Rx reviewFull TeleCareSpot review

More head-to-heads

Or browse alternatives to CoreAge Rx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.